# Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

> **NCT00022373** · PHASE3 · UNKNOWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Head and Neck Cancer
- Oral Complications of Radiation Therapy
- Radiation Toxicity

## Interventions

- **DRUG:** iseganan HCl oral solution
- **PROCEDURE:** management of therapy complications

## Key facts

- **NCT ID:** NCT00022373
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022373, "Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00022373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*